Illumina, Inc. (0J8Z.L)
USD 137.9
(-3.76%)
USD 137.9
(-3.76%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -1.06 Billion USD | 98.32% |
| 2022 | -4.17 Billion USD | -3297.56% |
| 2021 | -123 Million USD | -121.21% |
| 2020 | 580 Million USD | -41.12% |
| 2019 | 985 Million USD | 11.55% |
| 2018 | 883 Million USD | 45.71% |
| 2017 | 606 Million USD | 3.23% |
| 2016 | 587.03 Million USD | -4.21% |
| 2015 | 612.84 Million USD | 19.07% |
| 2014 | 514.71 Million USD | 283.81% |
| 2013 | 134.1 Million USD | -33.2% |
| 2012 | 200.75 Million USD | 0.65% |
| 2011 | 199.46 Million USD | -5.76% |
| 2010 | 211.65 Million USD | 68.52% |
| 2009 | 125.59 Million USD | 56.1% |
| 2008 | 80.45 Million USD | 126.71% |
| 2007 | -301.21 Million USD | -896.6% |
| 2006 | 37.81 Million USD | 276.3% |
| 2005 | -21.44 Million USD | -289.03% |
| 2004 | -5.51 Million USD | 79.29% |
| 2003 | -26.62 Million USD | 36.39% |
| 2002 | -41.85 Million USD | -38.05% |
| 2001 | -30.31 Million USD | -30.49% |
| 2000 | -23.23 Million USD | -292.59% |
| 1999 | -5.91 Million USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | 484 Million USD | 920.34% |
| 2024 Q3 | 741 Million USD | 53.1% |
| 2024 Q1 | -59 Million USD | -3.51% |
| 2023 Q4 | -57 Million USD | 92.44% |
| 2023 FY | -70 Million USD | 98.32% |
| 2023 Q1 | -64 Million USD | 49.61% |
| 2023 Q2 | -88 Million USD | -37.5% |
| 2023 Q3 | -754 Million USD | -756.82% |
| 2022 Q4 | -127 Million USD | 96.53% |
| 2022 FY | -4.17 Billion USD | -3297.56% |
| 2022 Q1 | 184 Million USD | 348.78% |
| 2022 Q2 | -579 Million USD | -414.67% |
| 2022 Q3 | -3.65 Billion USD | -531.61% |
| 2021 Q3 | -545 Million USD | -391.44% |
| 2021 Q4 | 41 Million USD | 107.52% |
| 2021 FY | -123 Million USD | -121.21% |
| 2021 Q1 | 193 Million USD | 46.21% |
| 2021 Q2 | 187 Million USD | -3.11% |
| 2020 Q3 | 162 Million USD | 68.75% |
| 2020 Q4 | 132 Million USD | -18.52% |
| 2020 Q1 | 189 Million USD | -29.48% |
| 2020 Q2 | 96 Million USD | -49.21% |
| 2020 FY | 580 Million USD | -41.12% |
| 2019 Q4 | 268 Million USD | -12.99% |
| 2019 FY | 985 Million USD | 11.55% |
| 2019 Q3 | 308 Million USD | 50.24% |
| 2019 Q2 | 205 Million USD | 0.49% |
| 2019 Q1 | 204 Million USD | 3.55% |
| 2018 Q4 | 197 Million USD | -18.26% |
| 2018 Q3 | 241 Million USD | 6.17% |
| 2018 FY | 883 Million USD | 45.71% |
| 2018 Q1 | 218 Million USD | -5.22% |
| 2018 Q2 | 227 Million USD | 4.13% |
| 2017 Q1 | 60 Million USD | -58.05% |
| 2017 Q3 | 181 Million USD | 26.57% |
| 2017 Q4 | 230 Million USD | 27.07% |
| 2017 FY | 606 Million USD | 3.23% |
| 2017 Q2 | 143 Million USD | 138.33% |
| 2016 Q1 | 121.44 Million USD | -15.66% |
| 2016 Q2 | 161.86 Million USD | 33.29% |
| 2016 FY | 587.03 Million USD | -4.21% |
| 2016 Q3 | 160.7 Million USD | -0.72% |
| 2016 Q4 | 143.01 Million USD | -11.01% |
| 2015 FY | 612.84 Million USD | 19.07% |
| 2015 Q3 | 140.78 Million USD | -7.34% |
| 2015 Q4 | 144 Million USD | 2.29% |
| 2015 Q1 | 176.12 Million USD | -13.19% |
| 2015 Q2 | 151.93 Million USD | -13.74% |
| 2014 Q1 | 92.09 Million USD | 24.82% |
| 2014 Q2 | 100.23 Million USD | 8.84% |
| 2014 Q3 | 119.49 Million USD | 19.21% |
| 2014 FY | 514.71 Million USD | 283.81% |
| 2014 Q4 | 202.88 Million USD | 69.79% |
| 2013 Q1 | -45.14 Million USD | -176.07% |
| 2013 Q3 | 45.46 Million USD | -24.23% |
| 2013 Q4 | 73.78 Million USD | 62.29% |
| 2013 FY | 134.1 Million USD | -33.2% |
| 2013 Q2 | 60 Million USD | 232.91% |
| 2012 FY | 200.75 Million USD | 0.65% |
| 2012 Q4 | 59.34 Million USD | 21.58% |
| 2012 Q1 | 49.61 Million USD | 81.74% |
| 2012 Q3 | 48.81 Million USD | 13.57% |
| 2012 Q2 | 42.98 Million USD | -13.37% |
| 2011 Q2 | 66.01 Million USD | -4.87% |
| 2011 Q4 | 27.29 Million USD | -25.75% |
| 2011 FY | 199.46 Million USD | -5.76% |
| 2011 Q3 | 36.76 Million USD | -44.31% |
| 2011 Q1 | 69.38 Million USD | 1.05% |
| 2010 Q2 | 47.42 Million USD | 24.08% |
| 2010 Q3 | 57.33 Million USD | 20.89% |
| 2010 Q4 | 68.66 Million USD | 19.76% |
| 2010 FY | 211.65 Million USD | 68.52% |
| 2010 Q1 | 38.22 Million USD | 48.81% |
| 2009 Q4 | 25.68 Million USD | -12.33% |
| 2009 Q2 | 36.1 Million USD | 4.62% |
| 2009 Q1 | 34.5 Million USD | -4.35% |
| 2009 FY | 125.59 Million USD | 56.1% |
| 2009 Q3 | 29.29 Million USD | -18.84% |
| 2008 Q4 | 36.07 Million USD | 2248.7% |
| 2008 Q2 | 23.87 Million USD | 25.81% |
| 2008 Q3 | 1.53 Million USD | -93.57% |
| 2008 FY | 80.45 Million USD | 126.71% |
| 2008 Q1 | 18.97 Million USD | 157.9% |
| 2007 Q4 | -32.76 Million USD | -308.58% |
| 2007 Q3 | 15.71 Million USD | 28.23% |
| 2007 Q2 | 12.25 Million USD | 104.13% |
| 2007 FY | -301.21 Million USD | -896.6% |
| 2007 Q1 | -296.4 Million USD | -1888.13% |
| 2006 Q3 | 15.25 Million USD | 133.85% |
| 2006 FY | 37.81 Million USD | 276.3% |
| 2006 Q4 | 16.57 Million USD | 8.67% |
| 2006 Q2 | 6.52 Million USD | 1305.73% |
| 2006 Q1 | -541 Thousand USD | -3481.25% |
| 2005 Q1 | -1.37 Million USD | -145.66% |
| 2005 Q2 | -18.54 Million USD | -1244.89% |
| 2005 Q3 | -1.53 Million USD | 91.71% |
| 2005 Q4 | 16 Thousand USD | 101.04% |
| 2005 FY | -21.44 Million USD | -289.03% |
| 2004 Q2 | -3.33 Million USD | 2.54% |
| 2004 Q4 | 3.02 Million USD | 269.66% |
| 2004 Q3 | -1.78 Million USD | 46.59% |
| 2004 Q1 | -3.42 Million USD | 9.95% |
| 2004 FY | -5.51 Million USD | 79.29% |
| 2003 Q3 | -5.34 Million USD | 37.09% |
| 2003 Q4 | -3.79 Million USD | 28.9% |
| 2003 FY | -26.62 Million USD | 36.39% |
| 2003 Q1 | -8.99 Million USD | 89.02% |
| 2003 Q2 | -8.49 Million USD | 5.54% |
| 2002 Q3 | 11 Million USD | 165.36% |
| 2002 FY | -41.85 Million USD | -38.05% |
| 2002 Q2 | -16.83 Million USD | -86.42% |
| 2002 Q1 | -9.02 Million USD | -1.08% |
| 2002 Q4 | -81.88 Million USD | -844.34% |
| 2001 Q1 | -6.69 Million USD | 0.87% |
| 2001 FY | -30.31 Million USD | -30.49% |
| 2001 Q4 | -8.93 Million USD | -22.69% |
| 2001 Q3 | -7.28 Million USD | 1.81% |
| 2001 Q2 | -7.41 Million USD | -10.79% |
| 2000 FY | -23.23 Million USD | -292.59% |
| 2000 Q3 | -5.38 Million USD | 6.55% |
| 2000 Q1 | -5.34 Million USD | 0.0% |
| 2000 Q2 | -5.75 Million USD | -7.79% |
| 2000 Q4 | -6.75 Million USD | -25.43% |
| 1999 FY | -5.91 Million USD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Editas Medicine, Inc. | -169.18 Million USD | -531.868% |
| Dynavax Technologies Corporation | -37.02 Million USD | -2787.004% |
| Supernus Pharmaceuticals, Inc. | -5.26 Million USD | -20188.48% |
| Perrigo Company plc | 151.9 Million USD | 803.752% |
| Thermo Fisher Scientific Inc. | 6.85 Billion USD | 115.585% |
| Iovance Biotherapeutics, Inc. | -460.55 Million USD | -132.109% |
| Walgreens Boots Alliance, Inc. | -14.07 Billion USD | 92.406% |
| IQVIA Holdings Inc. | 1.97 Billion USD | 154.072% |
| Heron Therapeutics, Inc. | -110.61 Million USD | -866.415% |
| Regeneron Pharmaceuticals, Inc. | 4.04 Billion USD | 126.414% |
| Unity Biotechnology, Inc. | -44.66 Million USD | -2293.266% |
| Waters Corporation | 817.67 Million USD | 230.736% |
| Biogen Inc. | 1.29 Billion USD | 182.434% |
| Sangamo Therapeutics, Inc. | -274 Million USD | -290.139% |
| Evolus, Inc. | -49.23 Million USD | -2071.308% |
| Adicet Bio, Inc. | -152.03 Million USD | -603.114% |
| Cara Therapeutics, Inc. | -121.49 Million USD | -779.872% |
| bluebird bio, Inc. | -244.26 Million USD | -337.645% |
| Esperion Therapeutics, Inc. | -155.56 Million USD | -587.181% |
| FibroGen, Inc. | -281.81 Million USD | -279.327% |
| Agilent Technologies, Inc. | 1.35 Billion USD | 179.185% |
| Corbus Pharmaceuticals Holdings, Inc. | -45.07 Million USD | -2271.482% |
| Homology Medicines, Inc. | -48.25 Million USD | -2115.314% |
| Geron Corporation | -193.94 Million USD | -451.19% |
| Alnylam Pharmaceuticals, Inc. | -282.17 Million USD | -278.843% |
| Amicus Therapeutics, Inc. | -73.49 Million USD | -1354.541% |
| Myriad Genetics, Inc. | -123.7 Million USD | -764.188% |
| Viking Therapeutics, Inc. | -100.82 Million USD | -960.232% |
| Intellia Therapeutics, Inc. | -515.29 Million USD | -107.456% |
| Zoetis Inc. | 3.06 Billion USD | 134.832% |
| Abeona Therapeutics Inc. | -48.2 Million USD | -2117.842% |
| Mettler-Toledo International Inc. | 1.08 Billion USD | 198.318% |
| BioMarin Pharmaceutical Inc. | 194.44 Million USD | 649.781% |
| Vertex Pharmaceuticals Incorporated | 4.3 Billion USD | 124.817% |
| Kala Pharmaceuticals, Inc. | -39.15 Million USD | -2630.314% |
| Ionis Pharmaceuticals, Inc. | -353.73 Million USD | -202.208% |
| Atara Biotherapeutics, Inc. | -276 Million USD | -287.31% |
| Verastem, Inc. | -92.08 Million USD | -1060.897% |
| Nektar Therapeutics | -137.42 Million USD | -677.879% |
| Axsome Therapeutics, Inc. | -231.82 Million USD | -361.124% |
| Aclaris Therapeutics, Inc. | -97.35 Million USD | -998.021% |
| Sarepta Therapeutics, Inc. | -267.82 Million USD | -299.143% |
| OPKO Health, Inc. | -157.02 Million USD | -580.801% |
| Exelixis, Inc. | 170.88 Million USD | 725.567% |
| Neurocrine Biosciences, Inc. | 250.9 Million USD | 526.066% |
| Corcept Therapeutics Incorporated | 107.28 Million USD | 1096.439% |
| Anavex Life Sciences Corp. | -55.75 Million USD | -1817.282% |
| uniQure N.V. | -282.87 Million USD | -277.911% |
| Imunon, Inc. | -21.03 Million USD | -4983.111% |
| Blueprint Medicines Corporation | -486.27 Million USD | -119.834% |
| Insmed Incorporated | -709.62 Million USD | -50.643% |
| Halozyme Therapeutics, Inc. | 337.57 Million USD | 416.671% |
| Agios Pharmaceuticals, Inc. | -391.48 Million USD | -173.061% |
| TG Therapeutics, Inc. | 20.63 Million USD | 5281.021% |
| Incyte Corporation | 620.52 Million USD | 272.273% |
| Emergent BioSolutions Inc. | -726.4 Million USD | -47.164% |